PremiumRatingsHologic’s Mixed Q2 Performance and Revised Earnings Guidance Lead to Hold Rating Hologic Exceeds Revenue Guidance Amid Challenges Hologic sees Q3 EPS $1.04-$1.07, consensus $1.10 PremiumThe FlyHologic price target lowered to $75 from $83 at Mizuho Hologic price target lowered to $70 from $86 at BofA Hologic price target lowered to $75 from $83 at RBC Capital PremiumThe FlyHologic downgraded to Hold from Buy at Argus Hologic obtains CE Mark for Affirm Contrast Biopsy Software Hologic announces FDA clearance of Aptima SARS-CoV-2 assay